Olaparib 150mg Tablets

Olaparib 150mg Tablets is a pioneering, first-in-class Poly (ADP-ribose) Polymerase (PARP) inhibitor that has revolutionized the landscape of precision oncology. This targeted therapy operates on the principle of “synthetic lethality.” In normal cells, PARP enzymes are crucial for repairing single-strand DNA breaks. Olaparib 150mg Tablets traps these PARP enzymes on the DNA, stalling the repair process. In cancer cells that already harbor defects in their Homologous Recombination Repair (HRR) pathway—most notably those with BRCA1 or BRCA2 mutations—this stalling leads to the accumulation of double-strand DNA breaks that the cell cannot fix. The inability to repair this genetic damage causes genomic instability and triggers apoptosis (programmed cell death). By exploiting this specific weakness in the cancer cell’s DNA repair machinery, the medication provides a highly effective, low-toxicity alternative to systemic chemotherapy. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for extending progression-free survival in patients with hereditary or acquired genetic defects.

The 150mg tablet strength is the standard formulation for the recommended adult dosage (typically 300mg twice daily, taken as two 150mg tablets). This formulation offers optimized bioavailability compared to earlier capsule versions, ensuring consistent therapeutic levels in the bloodstream. Olaparib 150mg Tablets represents a shift towards oral, maintenance-based cancer care, allowing patients to manage advanced malignancies effectively from home while preserving their quality of life.

Indications / Uses of Olaparib 150mg Tablets

Olaparib 150mg Tablets is commonly prescribed for the specialized management of the following genetically driven cancers:

• Ovarian Cancer Maintenance: It is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also a first-line maintenance treatment for patients with BRCA-mutated advanced ovarian cancer.
• Metastatic Breast Cancer: The medication is used for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
• Pancreatic Cancer Maintenance: Olaparib 150mg Tablets is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
• Prostate Cancer: It is prescribed for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

Key Features

• First-in-Class PARP Inhibition: The primary feature of Olaparib 150mg Tablets is its potent inhibition of PARP1, PARP2, and PARP3, making it a powerful weapon against DNA repair-deficient tumors.
• Synthetic Lethality Mechanism: It specifically targets cancer cells with BRCA mutations while largely sparing normal cells that have functional DNA repair pathways, reducing systemic toxicity.
• Oral Maintenance Therapy: The tablet form allows for a convenient, twice-daily oral regimen, enabling long-term disease control without the need for frequent hospital infusions.
• Significant Survival Benefit: Clinical trials (such as SOLO-1) have demonstrated that Olaparib 150mg Tablets can reduce the risk of disease progression or death by up to 70% in certain patient populations.
• CNS Penetration: The drug has demonstrated the ability to cross the blood-brain barrier, which is critical for treating metastases in the central nervous system.

Storage for Olaparib 150mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Olaparib 150mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the tablets in their original bottle to protect them from moisture. Do not remove the desiccant packet found inside the bottle. For maximum safety, always store Olaparib 150mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets. Do not transfer the medication to daily pill organizers unless they are moisture-resistant, as humidity can affect the tablet integrity.

Important Note on Olaparib 150mg Tablets

The administration of Olaparib 150mg Tablets requires strict adherence to safety guidelines. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), a potentially fatal secondary bone marrow cancer, has been reported in patients treated with PARP inhibitors. Patients must have their blood counts monitored at baseline and monthly thereafter. If prolonged severe hematological toxicity occurs, the drug should be interrupted and the patient evaluated.

Pneumonitis (inflammation of the lungs) is another rare but serious risk; patients presenting with new or worsening dyspnea, fever, cough, or wheezing should be evaluated immediately. Common side effects include nausea, fatigue, vomiting, and anemia. Nausea can often be managed by taking the dose with a light meal, although the tablets can be taken with or without food. Do not consume grapefruit or grapefruit juice while taking this medication, as it inhibits CYP3A4 and can dangerously increase the levels of Olaparib in the blood. The tablets must be swallowed whole; do not chew, crush, dissolve, or divide them. Olaparib 150mg Tablets can cause fetal harm (Pregnancy Category D); effective contraception is mandatory for women during treatment and for 6 months after the last dose, and for men for 3 months after the last dose. By strictly following these professional guidelines, patients can safely leverage the life-extending potential of Olaparib 150mg Tablets.